3 unknown, 2 completed, 1 recruiting, 1 terminated. 6 Phase 4, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Unknown 3, Completed 2, Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Thomas Benfield: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine, 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine - Hiv, Meningococcal Infections | Phase 4 | Recruiting | Thomas Benfield | 55 | 2021-04-28 | 2021-05-06 |
| Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] - Hiv, HIV Infections | Phase 4 | Unknown | Thomas Benfield | 126 | 2021-02-02 | 2021-05-27 |
| Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals Dolutegravir / Lamivudine Oral Tablet - Hiv, HIV Infections | Phase 4 | Completed | Thomas Benfield | 81 | 2020-10-22 | 2024-05-29 |
| Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia Convalescent anti-SARS-CoV-2 plasma, Infusion placebo - COVID, Corona Virus Infection | Phase 3 | Terminated | Thomas Benfield | 147 | 2020-05-01 | 2022-08-04 |
| Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia Shortened antibiotic treatment, Standard antibiotic treatment - Gram-negative Bacteremia, Urinary Tract Infection Bacterial | Phase 4 | Unknown | Thomas Benfield | 380 | 2020-03-11 | 2023-02-08 |
| Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia Intervention, Control - Community-acquired Pneumonia | Phase 4 | Completed | Thomas Benfield | 395 | 2019-09-18 | 2025-04-03 |
| Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia Antibiotic therapy duration for 7 days - Staphylococcus Aureus Bacteremia | Phase 4 | Unknown | Thomas Benfield | 284 | 2018-06-01 | 2020-10-19 |
Acquired Immunodeficiency Syndrome (3) · Bacterial Infections (2) · HIV Infections (2) · Body Weight Changes (1) · Cardiovascular Diseases (1) · Community-Acquired Pneumonia (1) · Coronavirus Infections (1) · Lung Diseases (1) · Meningococcal Infections (1) · Obesity (1) · Osteoporosis (1) · Pneumococcal Infections (1) · Pneumonia (1) · Pneumonia, Bacterial (1) · Pneumonia, Viral (1)
Lamivudine (2) · dolutegravir (2) · 13-valent pneumococcal vaccine (1) · 4CMenB vaccine (1) · Meningococcal Vaccines (1) · Methods (1) · Tenofovir (1) · abacavir, dolutegravir, and lamivudine drug combination (1) · doravirine (1)
Denmark (7)
Simone Bastrup Israelsen, MD (2) · Clara Clausen, MD (1) · Karen Brorup Heje Pedersen, MD (1) · Louise Thorlacius-Ussing, MD (1) · Michaela Tinggaard, M.D. (1) · Michaela Tinggaard, MD (1) · Nichlas Hovmand, MD (1) · Sandra Hansen, MD (1)
PMID 36180450, PMID 37156588, PMID 37479519, PMID 37604629
2019 (2), 2017 (1)